CareDx, Inc (NASDAQ:CDNA) Given Consensus Recommendation of “Hold” by Analysts

CareDx, Inc (NASDAQ:CDNA) has been assigned a consensus rating of “Hold” from the seven analysts that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have covered the stock in the last year is $30.60.

CDNA has been the subject of several recent research reports. HC Wainwright restated a “neutral” rating on shares of CareDx in a research report on Tuesday. BTIG Research upgraded shares of CareDx from a “neutral” rating to a “buy” rating and set a $40.00 price target for the company in a research report on Monday, August 19th. Craig Hallum upped their price target on shares of CareDx from $22.00 to $32.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Thursday, October 17th. Finally, The Goldman Sachs Group upped their price target on shares of CareDx from $26.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th.

Insider Activity at CareDx

In related news, insider Alexander L. Johnson sold 21,557 shares of the stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total value of $702,327.06. Following the completion of the transaction, the insider now owns 284,983 shares in the company, valued at $9,284,746.14. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Peter Maag sold 35,552 shares of the firm’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $33.04, for a total transaction of $1,174,638.08. Following the completion of the transaction, the director now owns 330,024 shares in the company, valued at approximately $10,903,992.96. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Alexander L. Johnson sold 21,557 shares of the firm’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $32.58, for a total transaction of $702,327.06. Following the transaction, the insider now owns 284,983 shares of the company’s stock, valued at approximately $9,284,746.14. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 91,340 shares of company stock worth $3,025,415 in the last 90 days. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On CareDx

Several large investors have recently made changes to their positions in CDNA. GAMMA Investing LLC boosted its position in shares of CareDx by 1,021.8% during the 2nd quarter. GAMMA Investing LLC now owns 2,210 shares of the company’s stock valued at $34,000 after purchasing an additional 2,013 shares in the last quarter. Plato Investment Management Ltd purchased a new stake in CareDx during the second quarter valued at about $62,000. nVerses Capital LLC lifted its stake in CareDx by 175.0% during the third quarter. nVerses Capital LLC now owns 3,300 shares of the company’s stock valued at $103,000 after buying an additional 2,100 shares in the last quarter. Meeder Asset Management Inc. purchased a new stake in CareDx during the second quarter valued at about $142,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in CareDx by 10,267.2% during the first quarter. Allspring Global Investments Holdings LLC now owns 18,661 shares of the company’s stock valued at $198,000 after buying an additional 18,481 shares in the last quarter.

CareDx Stock Performance

Shares of NASDAQ:CDNA opened at $23.14 on Wednesday. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -6.77 and a beta of 1.77. CareDx has a 1-year low of $4.80 and a 1-year high of $34.84. The company’s fifty day moving average is $29.46 and its two-hundred day moving average is $19.97.

CareDx (NASDAQ:CDNA) last issued its earnings results on Wednesday, July 31st. The company reported ($0.03) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.37. The company had revenue of $92.27 million for the quarter, compared to analysts’ expectations of $67.20 million. CareDx had a negative net margin of 53.73% and a negative return on equity of 53.65%. Sell-side analysts expect that CareDx will post -0.84 EPS for the current fiscal year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.